Navigation Links
Will Lipodissolve Continue to Remain Popular?
Date:12/12/2007

Leading Dermatologist Doing His Part to Warn Consumers

OMAHA, Neb., Dec. 12 /PRNewswire/ -- Lipodissolve, a treatment for unwanted fat, has been in the news for the past several years with significant controversy about its effectiveness and safety. Now, Fig, the parent company for up to 18 facilities around the country that offer this treatment and defender of this procedure, has closed its stores and is considering declaring bankruptcy. This is in addition to a longtime 'unsatisfactory' rating by the St. Louis Better Business Bureau, with 102 complaints over a year's period.

Despite the closure of this company, there are many companies still selling the non FDA approved substance, PC/DC, which is used for this procedure. Joel Schlessinger, M.D., Board-Certified Dermatologist and Board-Certified General Cosmetic Surgeon and immediate past-president of the American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS), has been involved in spotlighting the dangers of treatment. He is also involved in efforts to stop this treatment from being performed in his state, Nebraska. Just Monday, December 10th, Kansas enacted stricter restrictions on this procedure.

"It doesn't surprise me that Fig closed down -- the handwriting was on the wall when they received the unsatisfactory rating from the BBB. While I've been working on the Lipodissolve issue, many people have sustained harm from this unapproved procedure. Now, countless people have lost their money without any recourse due to the financial uncertainty of this company," says Schlessinger.

"Patient safety shouldn't be put in jeopardy for the sake of making a profit," said Joel Schlessinger M.D., founder of LovelySkin.com. "I've seen half a dozen cases of patients who received treatments and then had pain, swelling, bruising, bloating in the treatment areas, irregular dimpling and divots in the skin. Hopefully, this closure will stop some of this from happening."

Dr. Schlessinger is available for comment on Lipodissolve and its lack of safety. Interviews with Dr. Schlessinger are available and interested media may contact the company at 772-633-8337.

About Dr. Schlessinger

Joel Schlessinger M.D., board-certified dermatologist and general cosmetic surgeon, is the immediate past-president of ASCDAS and the Nebraska Dermatology Society. He continues to work with the FDA and the Nebraska State Board of Healing Arts to regulate Lipodissolve.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Joel Schlessinger, MD http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=35185


'/>"/>
SOURCE Joel Schlessinger M.D.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Lipodissolve - Is it Safe???
2. Battle Continues Over Vietnam PTSD Numbers
3. Continued Statin Use Boosts Post-Stroke Outcomes
4. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
5. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
6. Securians Minnesota Life Continues to Climb Group Life Rankings
7. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
8. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
9. United States continues to have highest level of health spending
10. LehmanMillet Continues Expansion with Strategic Hires
11. Pink Ribbon Bagels Continue the Fight for a Cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... a pilot study of ActiGraph’s CentrePoint Data Hub in a sample ... provider of clinical-grade wearable activity and sleep monitoring solutions for the global scientific ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
(Date:4/27/2017)... , ... April 27, 2017 , ... Healthcare companies are ... they will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare ... your executive resume and wondering if it’s as ready as you are for a ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion ... this year. , The first new location will open at the corner of ... 84th and Northern Lights Drive this fall. And the third location is in the ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 24, 2017 Solentim, the developer of ... addition of a major new product line called ... The VIPS has been developed for automatically seeding ... as part of the process to generate clonally-derived ... and more reliable solution when compared to traditional ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
Breaking Medicine Technology: